Semaglutide
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed for type 2 diabetes. It has since become one of the most clinically studied peptides for weight management, marketed as Ozempic and Wegovy.
Quick facts
- Half-life
- ~7 days
- Administration
- Subcutaneous injection (weekly)
- Primary use
- Weight management, blood sugar regulation
How it works
Semaglutide mimics the GLP-1 hormone, which is released after eating. It slows gastric emptying, reduces appetite by acting on the brain's satiety centres, and stimulates insulin secretion in a glucose-dependent manner.
Reported benefits
- Significant and sustained weight reduction
- Improved blood glucose control
- Reduced cardiovascular risk in diabetic patients
- Appetite suppression and reduced food cravings
Typical dosing protocol
Dosing
Starting at 0.25 mg/week, titrating up to 1–2.4 mg/week over several months
Cycle length
Long-term / ongoing under medical supervision
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Approved for medical use in the UK under prescription. Common side effects include nausea, vomiting, and diarrhoea. Must only be used under medical supervision.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.